AMAli Akbar Malekirad

Ali Akbar Malekirad

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ali Akbar Malekirad has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Melatonin for Sleep Quality and Occupational Cognitive Performance in Shift Workers with Low Sleep Quality: A Randomized, Double‐Blind, Placebo‐Controlled Clinical Trial

    by Sajad Khanjani, Ahmad Shamabadi, Shahin Akhondzadeh, Ali Akbar Malekirad

    About one‐third of the workers have irregular working hours, subsequently putting them at risk of sleep disorders. It also has negative impacts on employee performance. Sleep disorders and executive performance have been attributed to melatonin dysregulation due to long‐term exposure to artificial light. This study investigates melatonin effects on sleep quality and cognitive performance in employees with sleep disorders following shift work. Seventy‐two patients with sleep disorders following shift work were equally assigned to melatonin (5 mg before sleep at night after shifts) or matched placebo groups in a randomized, parallel‐group, double‐blind, placebo‐controlled design. Patients were assessed using the short Pittsburgh Sleep Quality Index (shortPSQI), Occupational Cognitive Failure Questionnaire (OCFQ), and adverse events at baseline and weeks 1 and 4. Data from 65 patients were analyzed. Baseline characteristics were comparable between the groups (p values >0.05). The melatonin group showed a greater reduction in total shortPSQI score from baseline to the first (p value = 0.018) and fourth (p value = 0.001) weeks, as well as in total OCFQ score to the fourth week (p value p value = 0.004) and OCFQ (p value p value = 0.042). Melatonin was safely and tolerably superior to placebo in treating patients with sleep disorders following shift work in the short term. Evidence also shows its effects on improving occupational cognitive performance in the medium term. The study protocol was registered and published prospectively in the Iranian registry of clinical trials (registration number: IRCT20090117001556N153).


  • Open Access

    Assessment of Some Toxic Metals in Ziziphora (Ziziphora persica) Obtained from Local Market in Lahijan, Northern Iran

    by Ebrahim Alinia-Ahandani, Ali Akbar Malekirad, Habibollah Nazem, Mohammad Fazilati, Hossein Salavati, Mohammad Rezaei

    : Heavy metals cause significant issues when people are exposed to many specific types of them. They can cause many disorders and affect the biochemical pathways in the body. Herbs are known as one of the richest sources of modern patented drugs, particularly in Iranian references. Many metals, particularly heavy metals, are toxic. Various studies have shown a higher level of heavy metals than standards in some countries like Iran, Pakistan, Egypt, and Nigeria. A preliminary study was conducted to determine some toxic elements in powdered Ziziphora (Ziziphora persica) collected from the local market in Lahijan city, northern Iran. Twenty random samples were gathered from various markets, and a flame atomic absorption spectrophotometer (FAAS) was used to detect some featured toxic elements, including copper (Cu), cadmium (Cd), lead (Pb), zinc (Zn), and mercury (Hg). The results showed higher Pb, Cd, and Hg levels than standards. Besides, Cu and Zn were detected to be lower than standards.


  • The Serum Oxidative Stress Biomarkers and Selenium Levels in a Group of Migraine Patients Compared with Healthy Controls: a Case–Control Study

    by Afsoon Talaie, Hanieh Jafary, Fardin Faraji, Ali Akbar Malekirad

    Migraine is one of the most common neurological disorders associated with recurrent attacks of moderate to severe headache. Oxidative stress may play an important role in migraine pathogenesis. This study aimed to measure and compare the serum levels of Selenium, total antioxidant capacity (TAC), and malondialdehyde) MDA (in migraine patients and healthy individuals. This case–control study was performed on 31 migraine patients and 30 age and gender-matched healthy controls. The severity of headache was assessed with a standard questionnaire, and the serum levels of Selenium (Se), MDA, and TAC were measured via biochemical methods. The odds of migraine were calculated across quartile of Se and oxidative stress biomarkers via binary logistic regression. Migraine patients had a significant lower Se levels (81.06 ± 8.66 vs. 88.94 ± 10.23 μg/L, P = 0.002) and a significant higher MDA levels (3.04 ± 1.74 vs. 2.06 ± 0.59 nmol/ml, P = 0.005) compared to healthy participants. Although serum TAC levels (1.34 ± 0.34 vs.1.37 ± 0.33 mmol/L, P = 0.755) were not significantly different between migraine patients rather than healthy subjects. Individuals in the lowest quartile of Se levels were about eleven times more likely to have migraine than those in the highest quartile (OR: 11.2; 95%CI: 1.57 to 80.2; P-trend: 0.016). Besides, being in the highest quartile of the serum MDA level, the odds of having migraine increases 15.4 times compared to the lowest quartile (OR = 15.4, 95%CI: 1.1 to 221, P = 0.044). No significant association was found between TAC and migraine. The lower Se and MDA levels in migraine patients gives rise to the probability which oxidant status may play an underlying role in migraine pathophysiology.